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In Brief
Transplanted organs may carry a
significant number of tissue-resident
lymphocytes, but their impact on
transplant outcome is unknown. Harper
et al. show that graft-versus-host
recognition by passenger CD4 T cells
within the allograft augments the
subsequent host immune response to the
allograft and hastens transplant rejection.
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Chronic rejection of solid organ allografts remains
the major cause of transplant failure. Donor-derived
tissue-resident lymphocytes are transferred to the
recipient during transplantation, but their impact on
alloimmunity is unknown. Using mouse cardiac
transplant models, we show that graft-versus-host
recognition by passenger donor CD4 T cells mark-
edly augments recipient cellular and humoral
alloimmunity, resulting in more severe allograft vas-
culopathy and early graft failure. This augmentation
is enhanced when donors were pre-sensitized to
the recipient, is dependent upon avoidance of host
NK cell recognition, and is partly due to provision of
cognate help for allo-specific B cells from donor
CD4 T cells recognizing B cell MHC class II in a
peptide-degenerate manner. Passenger donor lym-
phocytes may therefore influence recipient alloim-
mune responses and represent a therapeutic target
in solid organ transplantation.INTRODUCTION
Solid organ transplantation provides an effective therapy for pa-
tients with kidney, liver, heart, and pulmonary failure. Long-term
graft survival is limited by adaptive alloimmune responses
directed against transplant (typically allogeneic major histocom-
patibility complex [MHC]) antigens, that are expressed within the
organ and on endothelial cell surfaces and that interface with
circulating recipient immune cells. In addition, it is appreciated
that a substantial number of memory T cells reside within non-
lymphoid tissues (Mueller et al., 2013; Shin and Iwasaki, 2013;
Sathaliyawala et al., 2013). Solid organ allografts may therefore
deliver ‘‘passenger’’ donor lymphocytes to the recipient after
transplantation. Currently, little is known about whether passen-
ger lymphocytes remain in the allograft or reach recipient sec-
ondary lymphoid organs or how long they survive, given that their
likely recognition by natural killer (NK) cells might be expected to1214 Cell Reports 15, 1214–1227, May 10, 2016 ª 2016 The Authors
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solid organ transplantation remains unclear (Gill, 2010; Hadad
et al., 2014; van der Touw and Bromberg, 2010; Hidalgo et al.,
2010), and early transplant studies indicate that circulating donor
lymphocytes are often detectable in human transplant recipi-
ents, albeit in small numbers (Starzl et al., 1992a). Their presence
may manifest as devastating, acute graft-versus-host (GVH)
disease (Sharma et al., 2012), or as passenger lymphocyte syn-
drome, in which hemolysis is triggered by donor B cell recogni-
tion of mismatched ABO blood group antigens in the recipient
(Nadarajah et al., 2013). Thus, the impact of passenger lympho-
cytes on the recipient immune response to the allograft has still
to be clarified (Turner et al., 2014).
We have shown that in a murine heart transplant model with an
isolated MHC class II-mismatch [B6(C)-H2-Ab1bm12/KhEgJ
(bm12) to C57BL/6 (B6)], passenger bm12 CD4 T cell recognition
of I-AbMHCclass II on host B cells triggers the production of anti-
nuclear autoantibody, which causes allograft vasculopathy (Mo-
tallebzadehet al., 2012;Winet al., 2009).GVH recognitionbypas-
senger lymphocytesmayalsocontribute tograft rejection through
other mechanisms. For example, activation of host dendritic cells
(DCs) and macrophages following recognition of surface MHC
class II by donor CD4 T cells could prompt more vigorous host
alloimmunity from more effective processing and presentation
of graft alloantigen as self-restricted peptide fragments.
To examine the possibility that passenger donor lymphocytes
augment conventional host alloimmunity, we developed a mu-
rine transplant model incorporating a new bm12-derivative
donor strain that expresses additional MHC class I and class II
alloantigens to act as targets for conventional cellular and hu-
moral allorecognition (Ali et al., 2016). Here we describe how in
this model, heart allografts provoke autoantibody production in
B6 recipients as a consequence of GVH recognition by passen-
ger donor CD4 T cells. We show that even though donor CD4
T cells survive for only a few days after heart transplantation,
their survival provokes a marked and long-lasting augmentation
of cellular and humoral alloimmunity and results in early allograft
rejection. However, this augmentation is prevented in completely
mismatched strain combinations by rapid NK cell killing of donor
lymphocytes. These data have important clinical implications,
suggesting that partial MHC mismatch between donor andcommons.org/licenses/by/4.0/).
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BA Figure 1. Heart Allografts with Isolated
MHC Class I and Class II Disparities Pro-
voke Alloantibody and Donor CD4 T Cell-
Dependent Autoantibody Responses
(A) A series of backcrosses were performed to
generate the bm12.Kd.IE donor strain that differs
from B6 recipient mice at the I-A locus and mis-
matched H-2Kd and I-E loci.
(B and C) In contrast to syngeneic heart trans-
plants, bm12.Kd.IE heart allografts triggered
robust and durable IgG anti-Kd and (B) anti-I-E
alloantibody and (C) anti-nuclear autoantibody
responses.
(D and E) Responses were associated with (D)
complement C4d deposition on allograft endo-
thelium, which was not observed in allografts
transplanted into T cell-deficient Tcrbd/ re-
cipients (scale bars, 100 mm), and (E) development
of progressive allograft vasculopathy.
(F and G) Treatment of donor bm12.Kd.IE mice
with anti-CD4 mAb resulted in depletion of CD4
T cells (F) in the circulation and (G) within the heart
by the time of procurement of the heart graft
6 days later, as confirmed by flow cytometric
analysis of PBMC and heart allograft homogenate.
(H) The recipient splenic CD4 T cell population was
unaltered by the donor treatment, indicating that
antibody was not carried over to recipients.
(I) Depleting the donor CD4 T cell compartment
(CD4 deplete bm12.Kd.IE) abrogated recipient IgG
anti-nuclear autoantibody responses; these were
restored by adoptively transferring purified donor
CD4 T cells to recipients at the time of transplant.
*p < 0.05, **p < 0.01, and ***p < 0.001 (two-way
ANOVA in B, C, and I; Mann-Whitney test in E).
Data are representative of two independent ex-
periments (B–H; mean and SEM of n = 7 mice per
group in B, C, and E; n = 6 mice per group in F–H;
or n = 4 mice per group in D) or one experiment
(I; mean and SEM of n = 7 mice per group).recipient to promote NK cells responses against passenger lym-
phocytes may reduce alloimmune responses.
RESULTS
Heart Allografts with Isolated MHC Class I and Class II
Disparities Provoke Allo- and Autoantibody Responses
Human organs procured for transplantation, including kidney,
liver, and heart, contain significant populations of effector
and effector-memory CD4 and CD8 T lymphocytes (Figure S1).
We therefore sought to examine the impact of these passen-
ger donor lymphocytes on recipient adaptive alloimmune re-
sponses. To address this question, we developed amouse strainCell Rthat expressed multiple MHC alloanti-
gens, sufficient to stimulate cellular and
humoral alloimmunity, in addition to pro-
voking humoral autoimmunity. A series
of backcrosses were performed between
bm12, B6.Kd (Honjo et al., 2004b), and
B6.I-E (Conlon et al., 2012a) strains toderive the bm12.Kd.IE strain, which differs from the B6 recipient
strain at the classical MHC class I K and class II A and E loci
(H-2b, Kbd, Abm12, E, and Db; Figures 1A and S2).
When bm12.Kd.IE hearts allografts were transplanted into B6
recipients, the additional MHC class I H-2Kd and class II I-E mis-
matched alloantigens provoked strong alloimmune responses,
with production of long-lasting alloantibody to both antigens
(Figure 1B). Recipients also developed anti-nuclear autoanti-
body (Figure 1C) that was comparable in magnitude to the re-
sponses previously observed in B6 recipients of bm12 heart
allografts (Win et al., 2009; Motallebzadeh et al., 2012). These
antibody responses were associated with C4d complement
deposition on heart graft endothelium (Figure 1D), which waseports 15, 1214–1227, May 10, 2016 1215
not evident in syngeneic heart transplants, suggesting a humoral
component to the allograft vasculopathy that developed within
allografts by day 100 (Figure 1E).
GVH Allorecognition Provokes Recipient Humoral
Autoimmunity
To determine whether, as in the bm12 to B6model, autoantibody
production in B6 recipients of bm12.Kd.IE heart allografts was
due to donor CD4 T cell allorecognition of recipient I-Ab MHC
class II (Callaghan et al., 2012; Win et al., 2009), bm12.Kd.IE
donor mice were treated with depleting anti-CD4 monoclonal
antibody (mAb) before sacrifice. This resulted in profound deple-
tion of circulating and tissue resident CD4 T cell compartments
by the time of heart allograft procurement (Figures 1F and 1G).
Anti-CD4 antibody was not carried over to the recipient (Fig-
ure 1H); nevertheless, donor treatment with anti-CD4 mAb abro-
gated the recipient autoantibody response (Figure 1I), confirming
that passenger CD4 T cells within the bm12.Kd.IE donor heart are
responsible for initiating recipient humoral autoimmunity.
Despite the development of humoral autoimmunity, no overt
autoimmune disease was observed in kidney, liver, skin, or
native heart in B6 recipients up to 100 days after transplantation
with a bm12.Kd.IE heart allograft (Figure S3).
Augmentation of Conventional Alloimmunity by GVH
Allorecognition
The ability, through specific targeting of the donor CD4 T cell
population, to independently manipulate recipient autoimmune
and alloimmune responses provided a means to examine
whether GVH allorecognition augments host alloimmunity. Com-
parison of recipient cellular and humoral alloimmune responses
in recipients of unmodified and CD4 T cell-depleted bm12.Kd.IE
heart allografts revealed that alloantibody responses against the
H-2Kd alloantigen were substantially reduced in recipients of
CD4 T cell-depleted allografts (Figure 2A and S4). Responses
against the disparate donor MHC class II alloantigen were simi-
larly ameliorated (Figure 2B). Allo- and autoantibody responses
were restored in recipients of CD4 T cell-depleted bm12.Kd.IE
heart allografts by adoptive transfer of purified donor CD4
T cells at transplantation (Figures 1I and 2A).
The disparate H-2Kd alloantigen might be expected to act as a
target for recognition by recipient cytotoxic CD8 T cells (Harper
et al., 2015), but whereas B6 recipients of fullyMHC-mismatched
BALB/c heart allografts generated robust CD8 T cell responses,
the response in recipients of unmodified bm12.Kd.IE heart allo-
grafts was weak and transient (Figure 2C). Nevertheless, cyto-
toxic CD8 T cell responses were barely detectable in recipients
of CD4 T cell-depleted bm12.Kd.IE heart transplant recipients
at any time point (Figure 2C). Helper CD4 T cell alloresponses
were also examined in the recipient groups, by evaluating prolif-
eration of TCR75 CD4 T cells that were adoptively transferred
5 weeks after the heart transplant. TCR75 CD4 T cells recognize
Kd alloantigen via the indirect pathway (Ali et al., 2013) as self-
I-Ab-restricted, but not donor-I-Abm12-restricted, allopeptide
(Honjo et al., 2004a; Conlon et al., 2012b). In recipients of CD4
T cell-replete heart grafts, marked TCR75 T cell proliferation
was observed, indicating ongoing presentation of immunogenic
Kd allopeptide epitope. In contrast, TCR75 T cell responses in re-1216 Cell Reports 15, 1214–1227, May 10, 2016cipients of CD4 T cell-depleted hearts were approximately 50%
weaker (Figure 2D).
GVH Allorecognition Contributes to Allograft Rejection
The marked reduction in the alloimmune response to CD4 T cell-
depleted bm12.Kd.IE heart allografts ameliorated graft rejection,
in that vasculopathy was minimal in heart allografts from CD4
T cell-depleted donors and comparable to that observed in syn-
geneic heart transplants (Figure 3A). In addition, all heart trans-
plants from CD4 T cell-depleted donors were beating strongly
at day 50 (Figure 3B). Adoptive transfer of donor CD4 T cells
at time of transplant to recipients of CD4 T cell-depleted
bm12.Kd.IE heart allografts restored the development of allograft
vasculopathy (Figure 3A).
In contrast to human organs where memory T cell populations
dominate (Figure S1), the CD4 T cell compartment in mice
housed in specific-pathogen-free conditions is maintained in a
largely naive state.We therefore sought to examine howmemory
CD4 T cells within an allograft might influence host alloimmunity,
by priming Bm12.Kd.IE donors with a B6 skin graft 6 weeks
before procurement of the heart allograft to generate resident
memory T cells. Heart allografts from such donors were rejected
more rapidly by B6 recipients than were heart grafts from naive
donors, and they triggered augmented auto- and alloantibody
responses (Figures 3A–3D).
Recipient T and B Cells Are Essential Mediators of the
Accelerated Rejection Triggered by Early GVH
Recognition
Amplification of the recipient alloreactive T-B lymphocyte axis is
likely the principal mechanism by which donor CD4 T cell GVH
recognition triggers accelerated graft rejection, because host
germinal center (GC) alloantibody responses were less estab-
lished in recipients of T cell-depleted, than T cell-replete, heart
allografts (Figure 3E), as was complement C4d deposition on
allograft endothelium (Figure 1D). Similarly, heart grafts were
not rejected, and developed only minimal vasculopathy, when
transplanted into either B cell-depleted (Figure S5) or T cell-
deficient Tcrbd/ recipients (Figures 3A and 3B). To examine
whether the augmentation in recipient CD4 T cell responses trig-
gered by donor GVH recognitionwas dependent upon host B cell
immunity, B cell-depleted recipients were transplanted with
either CD4 T cell-replete or T cell-deficient bm12.Kd.IE heart
grafts, and proliferation of transferred TCR75 T cells was exam-
ined as earlier. For recipients of CD4 T cell-replete heart grafts,
proliferation of adoptively transferred TCR75 T cells was sub-
stantially less in B cell-depleted than in untreated recipients (Fig-
ure 2E) and approximated that observed in untreated recipients
of CD4 T cell-depleted bm12.Kd.IE heart allografts. Furthermore,
unlike B cell-replete recipients, proliferation of transferred
TCR75 CD4 T cells in B cell-depleted recipients was not influ-
enced by depletion of donor CD4 T cells (Figure 2E). The role
of recipient B cells in GVH-mediated augmentation of recipient
T cell alloreactivity does not simply reflect function as the
major cell population expressing target I-Ab for optimal GVH
activation of donor CD4 T cells, because the latter still divided
readily in B cell-depleted donors (Figure 3F), such that no
carboxyfluorescein succinimidyl ester (CFSE) staining was
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Figure 2. GVH Recognition by Passenger Donor CD4 T Cells within the Heart Allograft Augments Conventional Host Alloimmunity
(A and B) Anti-Kd IgG alloantibody responses in B6 recipients of bm12.Kd.IE heart allografts from CD4 T cell-depleted donors (CD4 deplete bm12.Kd.IE) were
significantly attenuated and restored by adoptive transfer of purified donor CD4 T cells to recipients at the time of transplant (A). Anti-I-E IgG responses were
similarly abrogated (B).
(C) Cytotoxic CD8 T cell alloresponses in B6 recipients of unmodified bm12.Kd.IE heart allografts were weaker than those observed in B6 recipients of BALB/c
heart grafts but significantly greater than those generated in recipients of CD4-T cell-depleted bm12.Kd.IE heart allografts.
(D and E) Indirect-pathway CD4 T cell responses, detected by quantifying proliferation of CFSE-labeled, Kd-allopeptide-specific TCR75 CD4 T cells transferred
4 weeks after transplant, expressed as a percentage of parent population divided (boxes; D), were similarly reduced in B6 recipients of CD4 T cell-depleted
bm12.Kd.IE heart allografts (E). Donor CD4 T cell-mediated augmentation of host indirect-pathway CD4 T cell responses was not observed in B cell-depleted B6
recipients (E).
*p < 0.05, **p < 0.01, and ***p < 0.001 (two-way ANOVA in A and B; Mann-Whitney test in C and E). Data are representative of two independent experiments
(A and B; mean and SEM of n = 6 mice per group) or one experiment (C–E; mean and SEM of n = 6 mice per group in C and E or n = 6 mice per group in D).
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B Figure 3. GVH Recognition by Passenger
Donor CD4 T Cells Accelerates Heart Allo-
graft Rejection but Is Dependent upon the
Host T-B Cell Axis
(A and B) Compared to B6 recipients of T cell-
replete bm12.Kd.IE heart allografts, allograft
vasculopathy was significantly less severe in
allografts from T cell-depleted donors (A), with all
hearts beating strongly at harvest (B); vasculop-
athy was restored by adoptive transfer of purified
donor CD4 T cells at transplant (CD4 reconstitu-
tion; A).
(C and D) Transplantation of B6 recipients with
heart allografts from bm12.Kd.IE donors chal-
lenged with a B6 skin graft (challenged donor)
provoked stronger (C) anti-nuclear IgG autoanti-
body and (D) anti-Kd IgG alloantibody responses,
with heart grafts rejected more rapidly (B).
(E) Allograft rejection is dependent upon host T
and B cells (A), with the kinetics of rejection and
the development of allograft vasculopathy in the
different experimental groups mirroring recipient
splenic GC activity.
(F) Host B cells are not required for optimal GVH
activation of donor CD4 T cells, because upon
transfer of CFSE-labeled bm12.Kd.IE CD4 T cells,
the alloreactive fraction (boxed) divided similarly
robustly in wild-type and B cell-depleted B6
recipients.
(G and H) Compared to wild-type B6 recipients,
transplantation of bm12.Kd.IE allografts into T cell-
deficient Tcrbd/ B6 recipients provoked similar
anti-nuclear IgG autoantibody responses (G) but
weak and transient anti-Kd IgG alloantibody with
higher levels of alloantibody than observed in
control naive serum achieved at week 1 (inset; H),
without development of splenic GC activity (E).
(I) Whereas adoptively transferred bm12.Kd.IE
CD4 T cells are readily detectable 7 days after
transfer into Rag-2/ B6 mice, they were unde-
tectable after transfer into wild-type B6 or
Tcrbd/ mice.
*p < 0.05, **p < 0.01, and ***p < 0.001 (Mann-
Whitney test in A, E, and H, inset [comparisons in A
and E are to the bm12.Kd.IE group]; log rank
[Mantel-Cox] test in B; two-way ANOVA in C, D, G,
and H). Data are representative of one experiment
(A–F and I; mean and SEM of n = 4 mice per group
in A–F or n = 3 mice per group in I) or two inde-
pendent experiments (G and H; mean and SEM of
n = 4 mice per group).detectable in the sub-population of alloreactive bm12.Kd.IE CD4
T cells as early as 3 days after transfer (Figure 3F).
Although transplantation of bm12.Kd.IE hearts into Tcrbd/
recipients prompted autoantibody and weak alloantibody re-
sponses (Figures 3G and 4H), there was no associated GC
activity (Figure 3E). Thus, the requirement for host CD4 T cells in
bm12.Kd.IE heart graft rejection appears to reflect provi-
sion of essential help for development of sophisticated host
humoral alloimmunity, a function not provided by donor CD4
T cells; transferred donor CD4 T cells are rapidly killed by adaptive
alloimmune recognition inB6hosts, becausewhereasbm12.Kd.IE
CD4 T cells were readily identified 7 days after transfer into
Rag-2/ hosts, they were undetectable following transfer into1218 Cell Reports 15, 1214–1227, May 10, 2016wild-type B6 hosts (Figure 3I). Hence, it is unlikely that the donor
CD4 T cells survive long enough to contribute directly to the pro-
gression of allograft vasculopathy. Their effect appears to be
mediated principally through a relatively short-lived interaction
with host B cells, but prolonged augmentation of humoral alloim-
munity is dependent upon additional help from host CD4 T cells.
Peptide-Independent Recognition of the B Cell MHC
Class II Complex by Donor CD4 TCells Promotes Plasma
Cell Differentiation but Requires Concurrent B Cell
Receptor Ligation
In considering how donor CD4 T cells amplify humoral alloim-
munity, transfer of bm12 CD4 T cells into B6 hosts prompted
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Figure 4. Peptide-Independent Recognition
of the B Cell MHC Class II Complex by
Donor CD4 T Cells Promotes Plasma Cell
Differentiation but Requires Concurrent
BCR Ligation
(A) Seven days after transfer of bm12 CD4 T cells
into B6 hosts, flow cytometric analysis of the
splenic CD19+ve B cell compartment demon-
strates global upregulation of MHC class II
expression, which is not evident upon transfer of
syngeneic B6 CD4 T cells.
(B and C) Whereas intravenous transfer of
Tcrbd/ B6 mice with bm12 CD4 T cells pro-
voked anti-nuclear IgG autoantibody (B), only
those mice simultaneously immunized subcuta-
neously with ovalbumin (OVA) protein developed
anti-OVA IgG (C).
(D and E) Similarly, intravenous transfer of
Tcrbd/ B6 mice with either purified bm12 CD4
T cells or bm12 CD4 T cells that expressed H-2Kd
transgene (bm12.Kd) provoked anti-nuclear IgG
autoantibody (D), but anti-Kd IgG alloantibody was
only generated in Tcrbd/ B6 mice that received
bm12.Kd CD4 T cells (E).
(F and G) Adoptive transfer of purified bm12.Kd
CD4 T cells into T cell-deficient Tcrbd/ bm12
recipients of a BALB/c heart allograft confirmed
not only that bm12 and bm12.Kd CD4 T cells can
provide help for generating humoral alloimmunity,
as determined by flow cytometric detection of
bound test sera to target BALB/c BMDCs (F) but
also that bm12.Kd CD4 T cells are tolerant of self
(I-Abm12)-restricted H-2Kd peptide and do not
provide help for generating anti-Kd IgG alloanti-
body (G).
*p < 0.05, **p < 0.01, and ***p < 0.001 (Mann-
Whitney test in C and F; two-way ANOVA in E
and G). Data are representative of three indepen-
dent experiments (A; n = 6 mice per group) or one
experiment (B–G; mean and SEM of n = 4mice per
group).upregulation of MHC class II expression on mature B cells (Fig-
ure 4A), in keeping with global activation from recognition of all
allogeneic MHC class II complexes on their surface. Yet only a
limited repertoire of antibodydirectedagainst nuclear self-antigen
was produced (data not shown). To examine the hypothesis that
plasma cell differentiation requires B cell receptor (BCR) ligation,
in addition to cognate interaction between theMHC class II com-
plex and the donor CD4 T cell, Tcrbd/B6micewere challenged
with purified bm12 CD4 T cells and immunized with ovalbumin
(OVA) protein. In this situation, CD4 T cell help for humoral re-
sponses can only be provided by the transferred donor CD4
T cells. Control Tcrbd/ mice received bm12 CD4 T cells only.
As expected,mice in both groups developedanti-nuclear autoan-
tibody, but anti-OVA immunoglobulinG (IgG) responseswere only
detectable in the group immunizedwith OVA (Figures 4B and 4C).
Similarly, challenge of Tcrbd/ B6 mice with CD4 T cells from
bm12 mice that expressed transgenic H-2Kd antigen (bm12.Kd)
provoked autoantibody, but also strong anti-Kd IgG alloantibody,
which was not observed in Tcrbd/ B6 mice challenged with
bm12 CD4 T cells (Figures 4D and 4E). Bm12.Kd CD4 T cells areselected against reactivity to self (I-Abm12)-restricted Kd peptide
and are unable to provide help to Kd-specific bm12 B cells for
generating anti-H-2Kd antibody (Figures 4F and 4G). Thus, their
provision of help for generating anti-H-2Kd antibody in B6 hosts
reflects peptide-degenerate direct-pathway allorecognition of
I-Ab MHC class II on H-2Kd-specific B6 B cells that, with simulta-
neousBCR ligation, provokesclass-switchedalloantibody.These
alloantibody responses presumably explain why bm12.Kd.IECD4
T cells are undetectablewithin aweek of transfer intoB6Tcrbd/
mice but survive long term in Rag-2/ mice (Figure 3I). In sum-
mary, despite being tolerant of H-2Kd antigen on the bm12 back-
ground, bm12.Kd CD4 T cells provoke anti-Kd alloantibody when
transferred into B6 hosts; this alloantibody results in rapid
destruction of the bm12.Kd CD4 T cells.
NK Cell Allorecognition Is Essential for Preventing
GVH-Mediated Amplification of the Host Adaptive
Alloimmune Response
Whether the amplification of host humoral immunity by GVH
recognition is an intrinsic component of the alloresponse or isCell Reports 15, 1214–1227, May 10, 2016 1219
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B Figure 5. NK Cell Allorecognition Is Essen-
tial for Preventing GVH-Mediated Amplifi-
cation of the Host Adaptive Alloimmune
Response
(A) Flow cytometric analysis of the peripheral
blood mononuclear cell fraction demonstrates
that whereas B6, bm12, and bm12.Kd CD4 T cells
survive long-term following adoptive transfer into
Rag-2/ mice, BALB/c CD4 T cells are rapidly
undetectable.
(B–D) Analysis of sera 4 weeks after transfer
reveals that unlike transfer of bm12.Kd CD4
T cells, transfer of BALB/c CD4 T cells to
Tcrbd/ B6 mice does not provoke (B) anti-Kd
IgG alloantibody or (C) anti-nuclear IgG autoanti-
body. (D) In contrast, circulating BALB/c CD4
T cells are detectable 2 weeks after transfer into
B6 Rag-2/ mice depleted of NK cells by
administration of anti-NK1.1 mAb, and their
transfer into NK cell-depleted Tcrbd/ B6 mice
provokes (B) anti-Kd IgG alloantibody and (C) anti-
nuclear autoantibody.
(E) Anti-nuclear autoantibody responses are not
generated by adoptive transfer of BALB/c CD4
T cells into wild-type B6 mice unless NK cells are
first depleted.
*p < 0.05, **p < 0.01, and ***p < 0.001 (two-way
ANOVA in A and E; Mann-Whitney test in B–D).
Data are representative of two experiments
(mean and SEM of n = 4 mice per experimental
group).dependent upon the degree of MHC mismatch between donor
and recipient has not been addressed. Given that donor
bm12.Kd.IE CD4 T cells survive long term in Rag-2/ B6 hosts
(Figure 3I), we examined whether innate immune evasion, and
specifically lack of NK cell allorecognition of donor lymphocytes,
was critical in triggering autoantibody generation. In this regard,
CD4 T cells purified from the completely mismatched BALB/c
donor strain did not survive when injected into B6 Rag-2/
hosts and did not provoke humoral auto- or alloimmunity upon
injection into B6 Tcrbd/ mice (Figures 5A–5C). This contrasts
with long-term survival and development of strong IgG allo-
and autoantibody when purified CD4 T cells from the less mis-
matched strains were injected (Figures 5A–5C). Furthermore,
depletion of NK cells by administration of anti-NK1.1 antibody,
in the B6 Rag-2/ recipients, resulted in long-term survival of
transferred BALB/c CD4 T cells and, in Tcrbd/ recipients, pro-
voked class-switched auto- and alloantibody responses (Figures
5B–5D) that were even stronger than those observed upon
administration of CD4 T cells from the less mismatched donor
strains. NK T cells, which also express NK1.1, do not develop
in Tcrbd/ mice (Figure S6); these experiments therefore serve
as an apposite control that the administered anti-NK1.1 antibody
is acting principally upon NK cells. Irrespective of GVH recogni-
tion, injection of BALB/cCD4 T cells into wild-type, immunocom-
petent B6 mice would be expected to provoke alloantibody, but1220 Cell Reports 15, 1214–1227, May 10, 2016autoantibody was only produced if host NK cells were depleted
simultaneously (Figure 5E), confirming that elimination of the
transferred donor CD4 T cell population, by either host cytotoxic
CD8 T cell or alloantibody responses, does not occur quickly
enough to obviate a GVH response and that NK cell allorecogni-
tion is instead essential for its prevention.
Host NK Cell Allorecognition Prevents Donor Passenger
Lymphocytes from Triggering Accelerated Rejection of
Completely MHC-Mismatched Allografts
These observations suggest that GVH-mediated amplification of
host alloimmune effector responses is normally prevented in
MHC-mismatched transplant models by host NK cell alloreactiv-
ity. The role of NK cells in rejection of completely mismatched
BALB/c hearts by B6 recipients was therefore examined. How-
ever, in this model of acute rejection, unmodified B6 recipients
reject BALB/c heart allografts within days, and it seemed unlikely
that host NK cell depletion would influence such a robust rejec-
tion response. Instead, a further model of chronic alloantibody-
mediated allograft vasculopathy was developed in which B6
Tcrbd/ recipients of BALB/c heart allografts are reconstituted
at transplantation with B6 TCR75 CD4 T cells but at limiting
numbers (103 per mouse), such that rejection occurs slowly
and is mediated by anti-H-2Kd GC alloantibody responses,
with help provided by differentiation of the transferred TCR75
T cells to follicular helper T cells (Figure 6A). In contrast to the
gradually evolving anti-Kd alloantibody responses observed in
NK cell-replete recipients, responses in the NK cell-depleted re-
cipients were stronger (Figure 6B), and the heart grafts were re-
jected within the first week (Figure 6C). Autoantibody was also
generated in the NK cell-depleted recipients (Figure 6D), con-
firming the development of GVH responses mediated by donor
BALB/c CD4 T cells. Critically, autoantibody generation, the
augmented alloantibody response, and rapid allograft rejection
were ameliorated in NK cell-depleted recipients by depletion of
CD4 T cells from the BALB/c donor before heart graft procure-
ment (Figures 6B–6D).
Finally, to test the relevance of our findings to amodel in which
graft rejection is prevented by administration of immunosup-
pression, as occurs routinely in clinical practice, heart allografts
from BALB/c donor mice that had been challenged 6 weeks
earlier with a B6 skin graft were transplanted into B6 recipients
that were treated with anti-CD154monoclonal antibody at trans-
plantation. In B6 recipients of heart grafts from unmodified do-
nors, this protocol results in long-term allograft survival (Larsen
et al., 1996; Ali et al., 2016), without development of autoanti-
body (Figure 6E), but in recipients of heart allografts from
challenged donors (that contained memory passenger CD4
T cells), depletion of NK cells at transplantation resulted in devel-
opment of anti-nuclear autoantibody and more pronounced
splenic GC activity (Figures 6E and 6F). Despite the robust
GC response, anti H-2Kd alloantibody responses were not
observed (data not shown). Depletion of CD4 T cells in the donor
before heart allograft procurement abrogated the autoantibody
response (Figures 6E and 6F).
DISCUSSION
Although the presence of donor lymphocytes in the circulation of
recipients of solid organ allografts was first demonstrated more
than 2 decades ago (Starzl et al., 1992a, 1992b), the extent to
which they affect recipient alloimmunity has remained unclear.
Clarification of the contribution of passenger donor lymphocytes
to graft rejection has become more pertinent with the realization
that non-lymphoid tissue contains substantial populations of
either resident or circulating memory T lymphocytes, and their
presence has been described within all solid organs currently
transplanted in humans (Casey et al., 2012; Sathaliyawala
et al., 2013). Here, we used a combination of donor CD4 T cell
depletion and adoptive transfer of donor CD4 T cells, in conjunc-
tion with transplantation of heart allografts from primed donors,
to demonstrate that GVH allorecognition by donor CD4 T cells
augments recipient alloimmunity and that this augmentation is
more pronounced for allografts procured from donors sensitized
against recipient MHC. Our findings thus reveal a mechanism by
which donor lymphocytes may influence graft rejection and sug-
gest that their impact may be more important than previously
considered.
Pivotal to this augmentation of host alloimmunity is the ability
of donor CD4 T cells to recognize host MHC class II via the direct
pathway (Ali et al., 2013). This provides an unusual form of pep-
tide-degenerate help, reflecting the unique nature of direct-
pathway allorecognition (Macdonald et al., 2009; Ali et al.,2013), in which the precursor frequency of CD4 T cells that
respond to a particular MHC class II alloantigen is 100- to
1,000-fold greater than for the response against conventional,
self-restricted peptide antigen, because all MHC class II alloan-
tigen complexes are recognized as foreign, irrespective of bound
peptide. This results in activation of all recipient B cells, but we
detail that differentiation to an IgG antibody-secreting plasma
cell is dependent upon simultaneous B cell receptor ligation.
Thus, although donor CD4 T cells can provide help to recipient
B cells in an antigen-independent fashion, antigen specificity is
maintained through the requirement for B cell receptor ligation.
This atypical help does not, however, completely replicate con-
ventional cognate help provided by CD4 T cells with self-
restricted specificity for peptide derived from target antigen,
because although GVH recognition by donor CD4 T cells could
trigger auto- and alloantibody responses, these were not sus-
tained in the absence of a recipient CD4 T cell population, and
allograft rejection did not occur. Our findings thus reveal an inter-
action between donor and recipient T and B lymphocytes, as
depicted in Figure 7.
Passenger lymphocytes only augmented recipient alloimmun-
ity if they were not eliminated rapidly by recipient NK cells. The
contribution of NK cell alloresponses to allograft rejection is still
debated (Gill, 2010; Hadad et al., 2014; van der Touw and Brom-
berg, 2010). It has been suggested that host NK cells promote
allograft rejection (Maier et al., 2001;Uehara et al., 2005; Kroemer
et al., 2008) either through the destruction of opsonized donor
cells or perhaps through regulation of T cell immunity (Maier
et al., 2001). Our results suggest the converse: that a major func-
tion of NK cells is inhibition of destructive cellular and humoral
alloimmunity that is triggered by passenger CD4 T cell GVH
recognition. This accords with several studies reporting a key
role for NK cells in allograft tolerance (Beilke et al., 2005; Yu
et al., 2006). The mechanisms by which NK cells promote toler-
ance in these studies have not been firmly established, but inhibi-
tion of recipient alloimmune responses through killing of donor
DCs may be important (Yu et al., 2006); in support, Laffont et al.
(2008) have reported that NK cell-mediated destruction of donor
DCs downregulates CD4 T cell alloimmunity. The different mech-
anism highlighted by our study—the killing of passenger lympho-
cytes—may be more clinically relevant, because irrespective of
NK cell allorecognition, adaptive alloimmune recognition would
be expected to result in prompt destruction of donor DCs; in
the Laffont et al. (2008) study, CD8a/ mice were studied to
obviate rapid killing by cytotoxic T lymphocytes. Our results
reveal that the critical window for passenger donor CD4 T cells
to augment host alloimmunity is within the first few days after
transplant and that evasionofNKcell-mediated killing is essential
for this effect. DonorCD4Tcells prompt host adaptive responses
that engender their own rapid destruction, but the delay in devel-
opment of these responses, at most a few days when compared
to NK cell recognition, is sufficient for GVH recognition to occur.
What are the implications of our study for clinical solid organ
transplantation? One could argue, on the basis of the derived
nature of the bm12.Kd.IE donor strain and the lack of require-
ment for administration of immunosuppression, that the clin-
ical relevance is limited. Similarly, it is perhaps surprising that
passenger donor lymphocytes were present in sufficiently largeCell Reports 15, 1214–1227, May 10, 2016 1221
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Figure 6. Host NK Cell Alloreactivity Is Critical for Preventing Donor Passenger Lymphocytes from Augmenting Host Adaptive Alloimmunity
(A) A model of alloantibody-mediated allograft vasculopathy was developed in which 103 TCR75 CD4 T cells are transferred into B6 Tcrbd/mice at transplant
with a BALB/c heart allograft.
(B–D) In contrast to reconstituted Tcrbd/ (CD4+ve Tcrbd/) recipients, depletion of NK cells in the reconstituted Tcrbd/ recipients (NK cellve host) results in
(B) more rapid allograft rejection, (C) stronger anti-Kd IgG alloantibody responses, and (D) generation of anti-nuclear autoantibody. The impacts of recipient NK
cell depletion were ameliorated by depleting CD4 T cells in donor mice (CD4ve donor, NK cellve host) before heart allograft procurement. Analysis of allograft
vasculopathy was not performed due to the rapid rejection of the NK cell-depleted recipient group.
(E and F) Acute rejection of BALB/c heart allografts was prevented by administration of anti-CD154 mAb at transplant to B6 recipients. (E) Anti-nuclear IgG
autoantibody responses are shown 5 weeks after transplant in recipients of heart allografts from unmodified BALB/c donors or from either BALB/c donors
challenged with a B6 heart allograft 6 weeks earlier or similarly primed BALB/c donors that were depleted of CD4 T cells before heart allograft procurement. An
additional group of recipients of allografts from primed donors were depleted of NK cells at transplant. (F) Corresponding splenic GC activity in the preceding
recipient groups 5 weeks after transplantation.
*p < 0.05, **p < 0.01, and ***p < 0.001 (log rank [Mantel-Cox] test in two-way ANOVA in B and C). Data are representative of two independent experiments (B–D;
mean and SEM of n = 5 mice per group B and D or n = 5 mice per group C).
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Figure 7. Proposed Model for Augmentation of Host Adaptive Alloimmunity by Passenger Lymphocytes
NK cell allorecognition normally results in rapid destruction of donor passenger lymphocytes within solid organ allografts (1). If NK cell allorecognition is avoided,
peptide-degenerate GVH recognition by donor CD4 T cells can activate all recipient B cells (2), but class-switched antibody secretion is dependent upon
simultaneous ligation of BCR with target antigen (3). Activated B cells drive enhanced activation of host CD4 T cells with indirect allospecificity (4), which provide
reciprocal help for development of GC alloantibody responses (5), presumably reflecting unique T follicular helper cell function of host CD4 T cells in providing
cognate, allopeptide-specific help (5). This results in long-term augmentation of humoral alloimmunity (6), with more rapid progression of allograft vasculopathy
and early allograft failure (7). Enhanced activation of indirect-pathway CD4 T cells may also contribute to allograft rejection through the provision of help for
generating heightened host CD8 T cell cytotoxic alloresponses (8).numbers within heart allografts to provoke such a marked
augmentation in the host’s alloimmune response. Against this,
CD4 T cells could be readily detected in all sampled human
organs that have been procured for transplantation but not
used. In addition, to counter concerns regarding the wider appli-
cability of the bm12.Kd.IE model, we employed an additional
model of chronic allograft vasculopathy using completely mis-
matched BALB/c donor and B6 recipient strains. This model
enabled clarification of the crucial role of host NK cells in killing
donor hematopoietic cells; nevertheless, the potential for pas-
senger donor lymphocytes to augment host alloimmunity was
again observed. We further demonstrated in this model that
memory donor CD4 T cells (as would be expected to be present
within human allografts) were able to provide co-stimulation-
independent help to naive recipient B cells for production of a
GC autoantibody response.
With regards the seemingly large numbers of donor lympho-
cytes contained within our murine heart allografts, our experi-
ments were not able to distinguish whether these were truly
resident within the parenchyma or trappedwithin themicrocircu-
lation of the heart allograft, and it is possible that different pro-curement and storage techniques used in clinical transplantation
denude a heart allograft of most of its passenger lymphocyte
populations. Against this, deliberate flushing of ourmouse hearts
via the coronary arteries at explant (as typically occurs in clinical
heart allograft procurement) did not make any appreciable differ-
ence to the numbers of CD4 T cells subsequently found within
the heart allograft (data not shown). In any event, we stress
that the heart allograft model was used as ameans of delineating
the precise mechanism by which donor CD4 T cells influence the
host’s response to an allograft. In this respect, whereas the
impact of passenger lymphocytes in clinical cardiac transplanta-
tion may be limited, lung, small bowel, and composite tissue
allografts will almost certainly transfer large numbers of donor
lymphocytes that originate from organized lymphoid tissue con-
tained within the allograft. Transplant outcomes for these organs
are poorer than for other organs; for example, a report of chronic
face allograft rejection described the development of autoim-
mune, scleroderma-type features consistent with skin manifes-
tations of chronic GVH (Petruzzo et al., 2015). One might
therefore predict that transplant outcomes would be particularly
poor for individuals that receive such organs from donorsCell Reports 15, 1214–1227, May 10, 2016 1223
matched for killer cell immunoglobulin-like receptor (KIR) recog-
nition (which occurs in approximately 50% of kidney transplant
pairings; van Bergen et al., 2011), because the avoidance of im-
mediate host NK cell detection would enable passenger donor
lymphocytes to potentiate host alloimmunity. However, the
impact of NK cell alloreactivity in transplant outcomes remains
uncertain (Tran et al., 2013; van Bergen et al., 2011), possibly
because studies to date have avoided the confounding impact
of human leukocyte antigen (HLA) mismatches on allograft sur-
vival by including only HLA-matched donor-recipient combina-
tions, whereas our findings suggest that KIR-ligand matching
would compromise transplant outcomes when donor and recip-
ient are mismatched additionally at the HLA class II loci.
It is likely that the ability of donor CD4 T cells to provide pep-
tide-independent help to host B cells has implications beyond
solid organ transplantation. In hematopoietic stemcell transplan-
tation, an association betweenchronicGVHdisease andhumoral
immunity is increasingly recognized (Nakasone et al., 2015; Du-
bovsky et al., 2014; Shimabukuro-Vornhagen et al., 2009; Sve-
gliati et al., 2007). Our findings suggest that this may relate to a
chimeric state in which the co-existence of populations of donor
and recipient T and B lymphocytes tends to provoke destructive
alloantibody responses. In addition, persistence of a mixed
chimeric state implies that reciprocal NK cell tolerance to donor
and host had been achieved (Narni-Mancinelli et al., 2013), which
maybeparticularly relevant to strategies for hematologicalmalig-
nancy that use less toxic, non-myeloablative conditioning to
initially establish mixed hematopoietic chimerism and then later
convert to full donor chimerism by infusion of donor lymphocytes
(Chang and Huang, 2013). Our findings suggest that inhibition of
host NK cell alloresponses may enable GVH recognition by CD4
T cellswithin the subsequent donor infusion to provide promiscu-
ous help for antibody production from residual host B cells that
are concurrently engaging target antigen. This may explain re-
ports documenting the development of humoral immunity
against tumor antigen following establishment of mixed hemato-
poietic chimerism (Bellucci et al., 2004; Kremer et al., 2014). Simi-
larly, the presence of donor CD4 T cells within donor lymphocyte
infusions has been associated with loss of donor mixed hemato-
poietic chimerism (Kim et al., 2004; Hock et al., 2014), but rather
than this being a bystander consequence of the general inflam-
matory milieu created by the GVH response (Hock et al., 2014),
our results suggest that the loss may instead be due to cognate
recognition ofMHCclass II on the surface of recipient alloreactive
B cells by donor CD4 T cells.
In summary, we demonstrate an unexpected role for donor
passenger CD4 T cells within allografts in the provision of help
to recipient B cells for generating humoral responses directed
against the transplant. Passenger donor lymphocytes may
therefore influence recipient alloimmune responses more pro-
foundly than previously considered and represent a therapeutic
target in solid organ transplantation.EXPERIMENTAL PROCEDURES
Animals
B6 (H-2b) and BALB/c mice (H-2d) were purchased from Charles River Labo-
ratories. Bm12 mice and T cell receptor-deficient mice (H-2b, Tcrbd/)1224 Cell Reports 15, 1214–1227, May 10, 2016B6.129P2-Tcrbtm1MomTcrdtm1Mom/J were purchased from The Jackson Labo-
ratory. Tcrbd/mice were backcrossed onto bm12 to create Tcrbd/.bm12
mice. B6 Rag-2/ mice (H-2b) were gifted by Prof. T. Rabbitts (Laboratory of
Molecular Biology). TCR-transgenic Rag-1/ TCR75 mice (H-2b), specific for
I-Ab-restricted H-2Kd54–68 peptide (Honjo et al., 2004a) and B6-Tg(K
d)RPb
(B6.Kd) mice, which express the full sequence of H-2Kd (Honjo et al., 2004b),
were gifted by Prof. P. Bucy (University of Alabama). B6.Kd mice were back-
crossed onto a bm12 background to create bm12.Kd mice. B6 mice that
lack I-Ab but express I-Ea (B6.I-E; Conlon et al., 2012a) were gifted by
Prof. C. Benoist (Joslin Diabetes Center). The F1 offspring of Bm12.K
d and
B6.I-E mice were bm12.Kd.IE. All animals were maintained in specific path-
ogen-free facilities, and experiments were approved by the UK Home Office
Animal (Scientific Procedures) Act of 1986.
Heterotopic Cardiac Transplantation
Fully vascularized cardiac allografts were transplanted intra-abdominally
(Conlon et al., 2012b). Rejection, defined as cessation of palpable myocardial
contraction, was confirmed at explant. Grafts were excised at predetermined
time points after transplantation and stored at 80C or fixed in 10% buffered
formalin. In certain experiments, heart allografts were retrieved from donor
mice challenged with a recipient strain skin allograft 6 weeks earlier, or
recipients were additionally injected intraperitoneally (i.p.) with 500 mg anti-
CD154 mAb (clone MR-1; BE0017-1; Bio X Cell) on days 2 and 0 in relation
to transplantation, a protocol that prevents acute allograft rejection but that
results in development of chronic allograft vasculopathy.
Dendritic Cell Purification and Culture
Bonemarrow-derived dendritic cells (BMDCs) were prepared as described pre-
viously (Curry et al., 2007). Briefly, bone marrow (BM) was flushed from femurs
and tibias with Hank’s balanced salt solution (Invitrogen). Cells were disaggre-
gated bypassing through a 40-mmmesh, andBMcells cultured in six-well plates
at 33 106/ml in 6-ml completemedium (RPMI 1640, 10% fetal calf serum [FCS],
100 IU/ml penicillin, 100 mg/ml streptomycin, and 2mML-glutamine; Invitrogen),
supplemented with murine granulocyte-macrophage colony-stimulating factor
(PeproTech) at 20 ng/ml and recombinant murine interleukin-4 (PeproTech) at
10 ng/ml. Cells were maintained by replacing half the culture medium with fresh
mediumonalternate days.Nonadherent cellswerediscardedonday4, andDCs
were used on day 8 for flow cytometric analysis.
Assessment of Recipient Humoral Immunity
Autoantibody Quantification
Anti-nuclear autoantibody responses were determined by HEp-2 indirect
immunofluorescence (The Binding Site), as described previously (Callaghan
et al., 2012), by incubating test sera on slides coated with HEp-2 cells and de-
tecting bound antibody with fluorescein isothiocyanate (FITC)-conjugated
goat anti-mouse IgG (STAR 70; Serotec). For each test serum, photomicro-
graphs were taken, and the intensity of staining was determined by integrated
morphometric analysis using MetaMorph software. The fluorescence value
was then derived by comparison with a standard curve, obtained for each
assay by serial dilutions of a pooled hyperimmune serum that was assigned
an arbitrary value of 1,000 fluorescence units.
Assay of Circulating Anti-MHC Class II I-E and Anti-BALB/c
Alloantibody
Sera were collected from experimental animals weekly and analyzed for anti-
I-E alloantibody (atweek 4 in the case of BALB/c alloantibody) by flow cytomet-
ric detection of binding to target cells. Briefly, targetB6.I-E andBALB/cBMDCs
were first blocked with anti-mouse CD16/CD32 (clone 2.4G2; BD Pharmingen)
and then incubated with serial dilutions (3-fold) of heat-inactivated test serum
for 30 min. Bound alloantibody was detected with FITC-conjugated goat
anti-mouse IgG (STAR70; Serotec), and cells were analyzed by flowcytometry.
For each sample, the geometricmean-channel fluorescencewas obtained and
plotted against dilution, and the areaunder thecurve (AUC)was thencalculated
as a percentage of the AUC of a standard of pooled hyperimmune sera.
Determining Circulating Anti-H-2Kd Alloantibody and
Anti-ovalbumin Antibody
Serum samples were collected from experimental animals weekly and
analyzed for the presence of anti-H-2Kd IgG alloantibody by ELISA. In brief,
96-well ELISA plates (Immulon 4HBX; Thermo Scientific) were coated with re-
combinant conformational H-2Kd at 5 mg/ml in Na2CO3-NaHCO3 buffer
(pH 9.6). Plates were blocked with 1% Marvel dried skimmed milk powder
(Premier International Foods), tripling serial dilutions of test sera added and
bound IgG antibody detected by incubating with biotinylated rabbit F(ab0)2
anti-mouse IgG (STAR11B; AbD Serotec) and ExtrAvidin Peroxidase conju-
gate (Sigma). Sure Blue substrate (KPL) was then added, the reaction was
stopped by the addition of 0.2 M H2SO4, and the absorbance (optical density
450) wasmeasured in a FluoStar Optima plate reader (BMGLabtech). For each
sample, an absorbance versus dilution curve was plotted, and the AUC was
calculated (Conlon et al., 2012a). The AUC of an experimental sample was ex-
pressed as the percentage of positive control (pooled hyperimmune) serum.
In certain experiments, mice were additionally immunized with OVA protein
100 mg in incomplete freund’s adjuvant subcutaneously. Anti-OVA antibody
was assayed in a similar fashion, and performed on test sera 4 weeks after
immunization, using an OVA-specific ELISA.
CD8 T Cell IFN-g Enzyme-Linked Immunospot
CD8 T cell enzyme-linked immunospot was performed as described (Sivaga-
nesh et al., 2013). Briefly, purified CD8 T cells were mixed with irradiated
BALB/c stimulator splenocytes and added toMultiscreen HTS filtration system
plates (Millipore) that had been coated with anti-mouse interferon-g (IFN-g; BD
Pharmingen) in 0.1 M bicarbonate buffer (pH 9.6). Plates were incubated at
37C and 5% CO2 for 20 hr, and after washing, spots were developed with
biotinylated rat anti-mouse IFN-g (BD Pharmingen), followed by streptavidin-
horseradish peroxidase and the substrate, H2O2, together with the 3-amino-
9-ethylcarbazole color indicator. Plates were read (Autoimmun Diagnostika),
and data were expressed as spot counts per 106 responder CD8 T cells for
each well.
Flow Cytometry
Antigen-presenting cell-conjugated anti-mouse CD4 (RM4-5), FITC-conju-
gated anti-mouse CD19 (1D3), R-phycoerythrin (PE)-conjugated anti-mouse
CD90.1/Thy1.1 (clone OX-7), PE-Cy7-conjugated anti-mouse CD4 (clone
L3T4), PE-conjugated anti-mouse H-2Kd (SF1-1.1), and FITC-conjugated
anti-mouse I-Ab (clone AF6-120.11) were purchased from BD Pharmingen.
Peripheral blood (depleted of erythrocytes by incubating with 0.17 M NH4Cl
red cell lysis buffer) and splenic single-cell suspensions were blocked with
anti-mouse CD16/CD32 (clone 2.4G2; BD Pharmingen), before staining with
the relevant antibodies and dead cell exclusion dye 7-aminoactinomycin D
(BD Pharmingen). All cells were analyzed on a FACSCanto II flow cytometer
with FACSDiva software (BD Biosciences).
T Cell Proliferation Assay
Single-cell suspensions of splenocytes obtained from TCR75 mice were
stained with 5 mM CFSE (Molecular Probes) in the dark for 5 min and then
quenched with 5% FCS/PBS. CFSE-stained splenocytes (2 3 106 to 5 3
106) were injected intravenously (i.v.) into recipient mice and spleens harvested
4 or 7 days later; flow cytometry was performed using allophycocyanin-conju-
gated anti-CD4 plus PE-conjugated anti-CD90.1/Thy1.1 to identify TCR75
T cells. Proliferation of wild-type bm12.Kd.IE CD4 T cells in B6 hosts was
assessed similarly, by analysis of CSFE-staining 3 days after transfer of
5 3 106 cells, with the caveat that in contrast to transfer of a monoclonal
population, analysis was restricted to the relatively small (5%) alloreactive
population nested within a large wild-type repertoire that did not undergo pro-
liferation. Proliferation was quantified using FlowJo (Tree Star).
Histology, Immunohistochemistry, and Immunofluorescence
Formalin-fixed hearts were paraffin mounted and stained using H&E and
Weigert’s Elastin van Gieson method to delineate the internal elastic lamina
and the severity of allograft vasculopathy assessed morphometrically, as re-
ported previously (Motallebzadeh et al., 2012). Complement C4d deposition
was assessed on 7-mm cryostat sections of donor heart allografts explanted
after 50 days by an avidin-biotin-peroxidase technique (Vector Laboratories),
using unconjugated rat anti-mouse C4 mAb (16D2; Abcam), as described pre-
viously (Win et al., 2009). GCs were quantified on 7-mm cryostat sections of
recipient spleens harvested 50 days following transplant by immunofluores-cence staining of B220+ B cells using rat anti-mouse B220 (clone RA3-6B2;
BD Pharmingen) detected with Cy3-conjugated goat anti-rat IgG (clone 112-
165-143, Jackson ImmunoResearch Laboratories) and peanut agglutinin
(PNA)+ GC B cells using FITC-conjugated PNA (Vector Laboratories), as
described previously (Conlon et al., 2012b). Numbers of PNA+ GC were ex-
pressed as a percentage of total (B220+) lymphoid follicles.
In Vivo Depletion and Transfer of Donor and Recipient Lymphocyte
Subsets
Donor mice were injected i.p. with 2 3 1.0 mg doses of depleting anti-CD4
mAb (YTS 191.1; hybridoma from the European Collection of Animal Cell
Cultures) 6 days and 1 day before heart graft procurement. Depletion of CD4
T cells (typically >99%) was confirmed by flow cytometric analysis of periph-
eral blood. To confirm cardiac parenchymal CD4 T cell depletion, donor hearts
were homogenized following incubation with collagenase digestion buffer, as
described previously (Sivaganesh et al., 2013), with a single-cell suspension
prepared by filtration through a 40-mm nylon cell strainer. CD4 T cells were
quantified by flow cytometry, with a mean of 5,137 CD4 T cells identified in
an untreated donor heart.
In certain experiments, recipients of CD4 T cell-depleted allografts were
adoptively transferred i.v. 13 107 donor CD4 T cells (purified with anti-mouse
CD4 MicroBeads (Mitenyi) using an autoMACS Separator (Mitenyi).
Depletion of themature recipient B cell population was achieved by injecting
i.p. 250 mg depleting anti-CD20 mAb (18B12; gifted by Cherie Butts at Biogen
Idec) 7 days before and 14 days after transplantation (Ueki et al., 2011). Deple-
tion of B cells was confirmed by flow cytometry of peripheral blood mononu-
clear cells (PBMCs) the day before heart transplantation.
Depletion of the recipient NK cell population was achieved by injecting
i.p. 500 mg depleting anti-NK1.1 (PK136; hybridoma from the European Collec-
tion of Animal Cell Cultures) 2 days and 1 day before transplant or cell transfer
and three times weekly thereafter. Depletion of NK cells was confirmed by flow
cytometry of PBMCs the day before transplantation or transfer.
Adoptive transfer studies of purified B6, BALB/c, bm12.Kd, and bm12.Kd.IE
CD4 T cells into B6, Tcrbd/, and Tcrbd/.bm12 mice were performed by
injecting i.v. 1 3 107 cells purified as earlier.
Statistics
Mann-Whitney U test was used for analysis of nonparametric data. Two-way
ANOVA was employed for comparison of intensity of HEp-2 fluorescence
scores and anti-H-2Kd antibody levels. Graft survival was depicted using
Kaplan-Meier analysis, and groups were compared by log rank (Mantel-Cox)
testing. Analysis was conducted using GraphPad 4 (GraphPad Software).
Values of p < 0.05 were considered significant.
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